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Introduction 
Percutaneous transluminal coronary angioplasty followed 
by a stent implantation is the first technique of the 
revascularization. Most of these stents are manufactured 
using cobalt chromium coated with iridium oxide or 
diamond-like carbon layers to prevent the formation of an 
oxide layer on their surface that is fragile and mechanically 
unstable under flow conditions.1 Despite the development 
of new coronary stent technologies, interactions of blood 
and cells with the implanted devices remain a serious 
cause of side effects. The major complications of their 
implantation are restenosis and late stent thrombosis 
(LST), which raises serious questions about their long-term 
safety. In-stent restenosis results from the proliferation of 
smooth muscle cells (SMCs).2 Late thrombus formation 
mechanism has not been fully explained yet, nevertheless, 
LST is thought to be associated with premature cessation 
of antiplatelet therapy in patients, stent malapposition, 
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Abstract
Introduction: The major complications 
of stent implantation are restenosis and 
late stent thrombosis. PBMA polymers 
are used for stent coating because of their 
mechanical properties. We previously 
synthesized and characterized Dextran-
graft-polybutylmethacrylate copolymer 
(Dex-PBMA) as a potential stent 
coating. In this study, we evaluated the 
haemocompatibility and biocompatibility 
properties of Dex-PBMA in vitro and in 
vivo. 
Methods: Here, we investigated: (1) 
the effectiveness of polymer coating under physiological conditions and its ability to release 
Tacrolimus®, (2) the capacity of Dex-PBMA to inhibit Staphylococcus aureus adhesion, (3) the 
thrombin generation and the human platelet adhesion in static and dynamic conditions,  (4) the 
biocompatibility properties in vitro on human endothelial colony forming cells (ECFC) and on 
mesenchymal stem cells (MSC) and in vivo in rat models, and (5) we implanted Dex-PBMA and 
Dex-PBMATAC coated stents in neointimal hyperplasia restenosis rabbit model.
Results: Dex-PBMA coating efficiently prevented bacterial adhesion and release Tacrolimus®. 
Dex-PBMA exhibit haemocompatibility properties under flow and ECFC and MSC compatibility. 
In vivo, no pathological foreign body reaction was observed neither after intramuscular nor 
intravascular aortic implantation. After Dex-PBMA and Dex-PBMATAC coated stents 30 days 
implantation in a restenosis rabbit model, an endothelial cell coverage was observed and the lumen 
patency was preserved.
Conclusion: Based on our findings, Dex-PBMA exhibited vascular compatibility and can 
potentially be used as a coating for metallic coronary stents.
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Material and Methods
Materials
Dextran (70 kg.mol-1) and FK-506 monohydrate 
(Tacrolimus TAC) were purchased from Sigma-Aldrich 
(St Quentin Fallavier, France). Butylmethacrylate (BMA) 
monomers, ceric ammonium nitrate and nitric acid were 
obtained from Acros (Illkirch, France). BMA monomers 
were purified by washing with NaOH (5%) and NaCl 
(20%) followed by distilled water three times. The coating 
was performed on electropolished CoCr disks (L615) 5 
mm in diameter and 0.5 mm thick and onto CoCr stents 
from Abbott Vascular (Rungis, France).
Dextran-PBMA copolymer synthesis and 
characterization
Copolymerization
The Dextran-PBMA copolymer (Dex-PBMA) synthesis 
was adapted from Derkaoui et al.23 Briefly, the reactions 
were carried out in a 1 L five-neck flask equipped with 
stirrer and condenser. The flask was immersed in a 
thermostated oil bath at 40°C and purged by nitrogen gas. 
Then 0.125 g of dextran was dissolved in 500 mL of 0.05 
M HNO3 for 10 min. Then, 5 mL of the solution of ceric 
ammonium nitrate dissolved in 0.2 M HNO3 (0.24 mM) 
and 2 g of BMA monomers were simultaneously added. 
After 40 min agitation, the pH was adjusted to 8 by the 
addition of 10 M NaOH aqueous solution and the solution 
was then concentrated in a rotavapor. The Dex-PBMA was 
precipitated in methanol and washed with 50 mL EDTA 
(10-2 M) to remove cerium, then lyophilized. To remove 
free PBMA homopolymer, the resulting product was 
extracted in acetone in a continuous extraction system 
(Soxhlet) for 6 hours, lyophilized and the Dex-PBMA 
powder was stored at room temperature. Twelve syntheses 
were performed and mixed to obtain a sufficient quantity 
of Dex-PBMA to carry experiments with a homogeneous 
batch.
Dex‑PBMA coating and Dex‑PBMA film preparation
Dex-PBMA polymer were coated either on glass coverslips, 
CoCr discs or CoCr stents, or prepared as a film. For that 
purpose, Dex-PBMA was dissolved in tetrahydrofuran 
(THF) and H2O at a ratio of 92:8 (v/v). Then 50 µL or 
1000 µL of a 30% (w/v) copolymer solution were loaded at 
the surface of a CoCr disc or glass coverslip, respectively, 
and left to evaporation 24 hours at room temperature in 
a saturated atmosphere of THF in the presence of CaCl2 
to absorb water. After drying (24 hours, 37°C) and UV 
sterilization, coated disc (Dex-PBMA disc) or coated-
glass coverslip were rinsed with phosphate buffered saline 
solution (PBS).
The stents, after deployment were dip-coated by 
immersion in a 20% (w/v) copolymer solution, evaporated 
in the presence of THF and CaCl2, dried 24 hours at 37°C, 
UV sterilized and washed in a saline solution (NaCl 0.9%). 
The Dex-PBMA-coated stents (Dex-PBMA stent) were 
mounted over a balloon and hand-crimped.
late re-endothelialization of the stent struts and the nature 
of polymer coating.3-6 In 45% of cases, they lead to patient 
death. 
In this context, three main approaches were developed 
to design safer drug-eluting stent (DES).7 The first one 
is polymer-free coating.8-10 Stent surfaces are micro-
porous or contain cavities where drugs are loaded. 
Nevertheless, the release control on these stents is 
difficult and the velocity is often too high.8,11,12 The second 
one consists of a biodegradable polymer coating that 
allows the drug-delivery during the degradation of the 
polymer.10,13 In this case, the polymer and its degradations 
products have to be biocompatible and not trigger any 
inflammatory reactions. Many biodegradable coatings 
were investigated.14,15 Alternatively, biodegradable stents 
were also developed.11,16,17 Nevertheless, side effects such 
as inflammatory reactions related to their degradation 
products have been reported.15 Clinical studies revealed 
that these bioresorbable stents led to an increased risk of 
stent thrombosis in comparison with DES. As a matter of 
fact, metallic stents appear to be the most adapted device 
to prevent coronary artery closure. The third approach 
is therefore based on a non-degradable polymer that 
protects the stent from corrosion. In vitro metallic stent 
backbone was shown to release degradation products 
leading to a possible allergic reaction or sensitization.18 
The polymer must be biocompatible and should promote 
endothelial coverage to prevent side effects in contact 
with blood.5 Recent studies suggest that the faster the re-
endothelialisation of the stented area is, the lower the risks 
of inflammation and thrombus formation are.19 The drug 
action and the polymeric coating materials themselves 
may inhibit the growth of endothelial cells, leading to 
disturbed vascular healing.20 In this context, it was stated 
that the stent platform, the drug and the polymeric drug 
carrier are all targets for DES improvement.19
Polymethacrylate polymers are widely used on medical 
devices for their mechanical properties and particularly 
the poly(n-butylmethacrylate) (PBMA) on several 
DES.21 Nonetheless, it is associated with another polymer 
because if the polymer is used on its own, its elasticity 
is too low to resist to stent deformation.21,22 Previous 
works have demonstrated that a copolymer of dextran, a 
natural polysaccharide, along with PBMA (Dex-PBMA) 
exhibits elastic properties suitable for stent coating.22 This 
combination promotes in vitro endothelial cell growth 
and inhibits the SMCs proliferation compared to PBMA 
alone.23 Besides, dextran is non-toxic and has already been 
approved by the US Food and Drug Administration for 
its clinical use for example as plasma volume expander.24
Therefore this study was undertaken to evaluate the 
haemocompatibility and biocompatibility of Dex-PBMA 
coated on glass coverslips and CoCr discs or stents, in vitro 
on coagulation, platelets and endothelial cells. Then more 
studies were performed ex vivo and in vivo in preclinical 
models of restenosis and intimal hyperplasia. 
Dex-PBMA coated stent biological evaluation
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For film preparation, 1.5 mL of 30% (w/v) of copolymers 
solution was poured into a 15 mm diameter Petri dishes. 
After solvent evaporation, drying and sterilization 
were performed in the same experimental conditions 
as described above. An 8 mm diameter circular punch 
purchased from Harris, Uni-Core (Redding, USA) was 
used to obtain round-shaped films. Then, Dex-PBMA 
films were washed in NaCl 0.9%.
For disc and stent associated with Tacrolimus 
(Dex-PBMATAC disc or stent), TAC (1 mg.mL-1) was 
dissolved in THF/water solution before Dex-PBMA in 
order to obtain Dex-PBMATAC solution. Then, disc or 
stent was coated in the same way as Dex-PBMA disc or 
stent.
Evaluation of Dex‑PBMA coating resistance under flow 
conditions
The coating resistance of Dex-PBMA stent was evaluated 
in vitro under dynamic conditions. For that purpose, 
Dex-PBMA stents (internal expanded diameter 4 mm, 8 
mm long) were expended in a silicon tube Versilic® (4 mm 
in internal diameter) from Nortec (St Etienne du Rouvray, 
France) and submitted to a coronary-physiological flow 
(shear rate 1000 s-1) in water at 37°C (n=3). During the 
same time-course experiment, Dex-PBMA stents were 
left in static condition (water, 37°C). After 7 days, samples 
were metalized with 5 nM of gold and observed using 
an environmental scanning electron microscopy (ESEM, 
XL30 ESEM-FEG Philips) with an accelerating voltage of 
20 kV at Hivac.
Water contact angle analysis
Contact angles were evaluated using the sessile drop 
method using a DSA 10 Kruss Instrument (Villebon-
sur-Yvette, France). A 1 μL water droplet was dispensed 
on the surface, and the contact angle determination for 
each sample was the average value of ten measurements 
on different parts of the samples: CoCr discs, Dex-PBMA 
discs and Dex-PBMATAC discs (n=3).
Biocompatibility tests
Blood collection and platelet isolation
Human whole blood was obtained from healthy 
volunteers exempt from medication for at least 10 days, 
after full informed consent was obtained, according to 
the Declaration of Helsinki. All experiments were carried 
out with fresh peripheral blood provided by the French 
blood bank institute (EFS) under an agreement with the 
INSERM U1148 (n°12/EFS/079). Blood was collected via 
venipuncture into siliconized Vacutainer™ tubes from 
Becton Dickinson (Le Pont de Claix, France) containing 
buffered sodium citrate (0.12 M, nine parts blood to one 
part sodium citrate solution) with the first tube being 
discarded. Whole blood was centrifuged at 120 g for 15 
minutes at room temperature to prepare platelet-rich 
plasma (PRP). For thrombin generation, platelet counts 
in PRP were adjusted to the desired concentration by 
dilution with autologous platelet poor plasma (PPP). 
PPP was prepared by centrifugation of the blood at 2,000 
g for 15 minutes. Alternatively, blood was collected on 
acid-citrate-dextrose anticoagulant (ACD-A) to prepare 
washed platelets as previously reported.25
Cell isolation and preparation
Human endothelial colony-forming cells (ECFCs) were 
isolated from human umbilical cord blood after the 
consent of mothers and the approval by the Biological 
Resources Center in the Cell Therapy Unit from Saint 
Louis Hospital (Paris, France), authorized by French 
Ministry of Research under number AC-2008-376 
and certified by the French Normalization Agency 
under number 201/51848.1. ECFCs were expanded in 
Endothelial Cell Growth Medium EGM2 from Ozyme 
(Montigny-Le-Bretonneux, France) and characterized as 
previously described.26 The presence of Weibel-Palade 
bodies, combined with the expression of endothelial 
markers (CD31, KDR, Tie-2, CD144), and dual positivity 
for DiI-AcLDL uptake and BS-1 lectin binding confirmed 
the endothelial phenotype of the ECFCs thus obtained. 
ECFCs do not express leukomonocytic markers such as 
CD45 and CD14. FACS analysis (FACS Calibur) from 
Becton Dickinson (Le Pont de Claix, France) was used 
to assess expression of endothelial-lineage cell surface 
antigens,26 Cells were used with cells culture for less than 
30 days.
Mesenchymal stem cells (MSCs) were isolated from 
bone marrow samples obtained after informed consent 
according to approved institutional guidelines (Assistance 
Publique-Hôpitaux de Paris, Paris, France). The bone 
marrow mononuclear cells were collected from ficoll 
gradients and cultured in minimum essential medium-α 
(MEM) from Invitrogen, ThermoFisher Scientific 
(Villebon sur Yvette, France), supplemented with 10% 
Foetal Calf Serum (FCS) from Gibco, ThermoFisher 
Scientific (Villebon sur Yvette, France), glutamax-I 
(2 mM) from Invitrogen, ThermoFisher Scientific 
(Villebon sur Yvette, France), basic Fibroblast Growth 
Factor FGF2 (1 ng.mL-1) from R&D Systems (Abingdon, 
UK) and antibiotic/antimycotic (1%) from Invitrogen, 
ThermoFisher Scientific (Villebon sur Yvette, France). 
Cells were used between passage 4 and 7.
Static platelet adhesion on Dex‑PBMA
Static evaluation of platelets adhesion was carried out on 
human washed platelets suspension (2.0 x 108 platelets/
mL) in reaction buffer (RB, NaCl 13.7 mM, KCl 0.1 mM, 
MgCl2 0.2 mM, Glucose 0.55 mM, HEPES 0.5 mM, 
NaH2PO4 30 µM, NaHCO3 0.12 mM, BSA 3 mg.mL-1, pH 
7.3). Dex-PBMA or CoCr disks were loaded into wells of 
a 96 wells plate coated with 10 mg.mL-1 of collagen type I 
(positive control, Horm collagen from Nycomed (Munich, 
Germany)) or 1% (w/v) of bovine serum albumin (BSA) 
in PBS. Washed platelets (20 000 000) were added into the 
wells and incubated for 1 hour at room temperature on 
a platform shaker. After two washes with RB, 100 µL of 
lysis solution (Na citrate 0.1 M, pNPP 1.3 mg.mL-1, triton 
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X-100 20 µL.mL-1) were added for 1 hour 30 incubation at 
37°C. The reaction was stopped with 25 µL of 1 M NaOH 
solution and supernatants were read at 405 nm (Fluostar 
Optima) from BMG Labtech (Champigny s/Marne, 
France). Each experiment was carried in three times and 
readings were made in duplicate. In order to observe the 
platelet morphology, Dex-PBMA or CoCr discs were fixed 
in 2.5% glutaraldehyde solution for 1 hour, dehydrated 
in ethanol and observed with Environmental Scanning 
Electron Microscopy (ESEM, XL30 ESEM-FEG Philips).
Dynamic platelet adhesion on Dex‑PBMA 
Dynamic evaluation of platelet adhesion was carried 
out on whole blood collected on 75 µM PPACK from 
Haematologic Technologies Inc. (Vermont, USA), then 
labelled with Dioc-6 (5 µM) from Interchim® (Montluçon, 
France) and perfused for 2 min at a shear rate of 1500 
s-1 over Dex-PBMA or collagen-coated glass coverslip 
inserted in the flow chamber from Maastricht Instruments 
(Maastricht, Netherlands). All experiments (n=3) were 
observed in real-time and videotaped for off-line analysis. 
Quantification of fluorescent adherent platelets within 
time (t) was processed from digital images with ImageJ 
software using the t0 image as the zero reference.
Thrombin Generation on Dex‑PBMA
Thrombin generation was measured in freshly prepared 
PRP (150 000 000 platelets.mL-1) and PPP by means of 
the Calibrated Automated Thrombogram (CAT) method 
from Thrombinoscope BV (Maastricht, The Netherlands) 
as previously described.27 Measurements were conducted 
with 80 μL PRP or PPP in a total volume of 120 µL in 
flat-bottom 96-well plates, containing Dex-PBMA and 
the CoCr discs. Thrombin generation was performed 
in the absence or presence of tissue factor (TF, 20 µL, 
0.5 pM and 1 pM final concentration for PRP and PPP, 
respectively). Dedicated software from Thrombinoscope®, 
Thrombinoscope BV (Maastricht, The Netherlands) 
enables the calculation of thrombin activity and displays 
thrombin activity against time. All experiments were 
carried out 6 times. Results were expressed in a proportion 
of a control Immulon 2HB well from Thermoscientific® 
(Illkirch, France). The velocity index (nM.min-1) was 
calculated from CAT parameters [VI=Peak/(time to Peak-
LagTime)]. LagTime (LT in min) is related to the initiation 
phase of coagulation and correspond to the generation of 
10 nM of thrombin, time to Peak (tPeak in min) and Peak 
(maximal dose of thrombin produced in nM) are related 
to the amplification phase of coagulation.
Cell adhesion and proliferation on Dex‑PBMA
One day before experiments, ECFCs and MSCs were 
growth-arrested for 18 h respectively in EBM2, 2.5% FCS 
and MEM Glutamax. They were then washed, detached 
with accutase from Sigma Aldrich (St Quentin Fallavier 
France) and suspended in the appropriate medium. All 
assays were performed in triplicate. Dex-PBMA or CoCr 
discs were placed at the bottom of 96-well plates. As a 
positive control some wells were coated with gelatin 0.2% 
(30 µL, 20 min at RT). All samples were passivated with 
FCS (50 µL, 20 minutes at 37°C).
For cell adhesion assay, ECFCs or MSCs cells were 
seeded onto disc at 25 000 cell.cm-2 in the appropriate 
medium. The cells were incubated either for 20 minutes 
or 2 hours at 37°C in 5% CO2 in a humidified incubator. 
After washing the disc with PBS to remove non-adherent 
cells, cell adhesion quantification was determined by 
pNPP from Sigma Aldrich (St Quentin Fallavier France) 
at 405 nM using a Fluostar optima from BMG Labtech 
(Champigny s/Marne, France). 
For cell proliferation assay, ECFCs or MSCs cells were 
seeded on each disc at 15 000 cell.cm-2 in their respective 
media. The cells were incubated for 3 or 4 days at 37°C in 
5% CO2 in a humidified incubator. On day 3 and day 4, 
cell proliferation was evaluated by pNPP assay. In all assay, 
results were expressed as a ratio of gelatin control (n=3).
Bacterial adhesion on Dex‑PBMA
The experimental procedure of the adhesion of 
Staphylococcus aureus CIP53136 obtained from Institut 
Pasteur (Paris, France) on Dex-PBMA film, CoCr disc and 
collagen (positive control) was adapted from Anagnostou 
et al.28 S. aureus was used because it is the main bacteria 
involved in stent infection.29
First, samples were incubated 1 hour at 37°C in FCS. The 
samples were then washed with PBS and then incubated 
with 1 mL of a suspension of S. aureus 108 colony forming 
units/ml (UFC/mL) concentration. After 1 hour of 
incubation at 37°C, samples were washed three times with 
PBS and incubated with 500 µL of trypsin. The removed 
bacteria were then spread on agar gel and cultivated 
overnight. Then, bacterial colonies were counted (n=3).
In vitro pharmacological drug-release studies
Dynamic perfusion systems were developed in order 
to study the release of a model molecule from the 
Dex-PBMA. The chosen molecule was tacrolimus (TAC). 
The circulation system was a flask containing perfusion 
medium - Dulbecco's Modified Eagles Medium (DMEM) 
from Invitrogen, ThermoFisher Scientific (Villebon sur 
Yvette, France) supplemented with sodium bicarbonate 
L-glutamine (2 mM, Invitrogen), penicillin/streptomycin 
(10 ml.L-1) from Gibco, ThermoFisher Scientific (Villebon 
sur Yvette, France) and FCS connected to a peristaltic 
pump and maintained at 37°C - in which one a stented 
artery was introduced. A physiological rate flow was then 
applied on the system (shear rate 1000 s-1) and 0.2 µm 
sterile filters allowed gas exchange. Arteries were removed 
from male Wistar rats (200-250 g, 8 week-old from Janvier 
Labs - CERJ (Le Genest St Isle, France) and cut in segments 
5–7 cm length. A Dex-PBMA or Dex-PBMATAC stent was 
then expanded into them (2.5 mm in diameter) and the 
arteries were placed into the circulating ex vivo system. 
1/500th of the perfusion medium was taken every day 
for 6 days. A specific assay was developed to quantify the 
concentration of TAC released in the collected samples 
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using an immunoaffinity bead-based flow cytometric 
test and the xMAP® technologies. Sheep polyclonal anti-
TAC from R&D Systems (Abingdon, UK) was covalently 
coupled to the fluorescent color-coded beads (BDTM 
Cytometric Bead Array). Before the assay and to control 
the bead grafting, the beads were incubated with a 
secondary fluorescent antibody (Rabbit anti-Sheep-FITC) 
from Pierce (Paris, France). In order to determine TAC 
concentration, samples were mixed with the previously 
grafted beads and kept in the dark (2 hours, RT). The 
captured TAC was detected using specific biotinylated 
anti-tacrolimus secondary antibody (HyTest LTD). After 
wash, streptavidin-phycoerythrin (PE) detection reagent 
was incubated with capture bead in the dark (15 min, 
RT). The acquisition was achieved on BD FACS array bio-
analyzer from BD Bioscience (San Jose, CA, USA). The 
intensity of fluorescence of yellow parameter (PE emits 
at 585 nm) is proportional to the amount of TAC present 
in samples. Standard curves of TAC (range 48-25,000 
pg.ml-1) were run in each assay.
In vivo implantation 
The procedures and the animal care complied with the 
“Principles of animal care” formulated by the European 
Union (Animal Facility Agreement n°75-18-03, 2005) 
and the protocol was approved by the ethical committee 
(authorization n°75–214, French Ministry of Agriculture).
Rat intramuscular and intra‑aortic implantations
Twelve healthy male Wistar rats (9 to 11 week-old, CERJ, 
France) were used for the study. The rats were sedated 
before and during each manipulation with Pentobarbital 
(0.1% v/w). 
Intramuscular implantation: Foreign body reaction 
to Dex-PBMA was first evaluated by intramuscular 
implantation. Dex-PBMA films were implanted in the 
abdominal wall of 9-weeks-old male Wistar rats and 
harvested after 7 and 30 days (n=3). After 48h of immersion 
fixation with 4% formalin, tissues were embedded with 
paraffin. Sections of 6 µm thickness were cut (Microm 
HM) from the middle part of the film, then deparaffined 
and stained with hematoxylin-eosin (HE) and Naphthol 
AS-D Chloroacetate esterase stains. The thickness of the 
cell cap was measured 5 times on HE histological sections, 
3 sections by rats (n=3), using the soft NDP view after 
scans by Nanozoomer from Hamamatsu (Hamamatsu 
City, Japan).
Intra-aortic implantation. Dex-PBMA stent coating was 
then evaluating. 11-weeks-old male Wistar rats received 
a standard diet and aspirin in water (1 mg.mL-1) 72 hours 
before implantation to sacrifice. A 2.25 mm-diameter 
8-mm-long stent was implanted through an abdominal 
aorta access. After a flush of the aorta with 200 U of heparin 
sodium from Pfizer (Paris, France), rats were sutured. An 
angiography was made after 30 days followed by sacrifice. 
Stented aortas were then harvested, fixed 72 hours with 
4% formalin and methyl methacrylate-embedded (Sigma, 
France) protocol adapted from Rippstein et al.30 Section 
of 10 µm thickness were cut from the middle part of the 
stent. Subsequently, sections were deplastified and stained 
with HE or immune-stained with alpha actin, RECA 
(endothelial cells) and CD-68 (macrophages - respectively 
MCA5781GA, clone HIS52 Bio-Rad and MCA341GA 
from Bio-Rad AbD Serotec (Kidlington, UK).
Implantation in a rabbit model of intimal hyperplasia
The protocol was adapted from Feldman et al.31 Three 
male New Zealand White Rabbits, weighing 3.5 to 4.7 
kg, were fed a 0.3% cholesterol diet, started 21 days 
before angioplasty. Animals were anesthetized with 
intramuscular ketamine 500 U, Xylazine and Vetranquil 
(14:8:4 v/v). All animals received heparin (1000 U) within 
the carotid before angioplasty. A 5F sheath was inserted 
in the left carotid artery. Intimal hyperplasia was induced 
by balloon angioplasty followed by stent implantation. 
Bilateral iliac artery angioplasty was performed with 
a 2.5-mm-diameter, 20-mm-long angioplasty balloon 
catheter (3 times 1-minute inflation at 8 atm). A 8-mm-
long and 2.75 mm in diameter coated stent mounted 
over the balloon, was implanted in both iliac arteries 
immediately after balloon angioplasty (30-second 
inflation at 10 atm), resulting in frank arterial overstretch 
(1.2 to 1.3 stent-to-artery ratio). Arterial blood was drawn 
before angioplasty and at euthanasia. The concentration 
in TNFα was evaluated before implantation and before 
sacrifice using Elabscience rabbit TNFα ELISA Kit to 
study the effect Dex-PBMA or Dex-PBMATAC on TNFα 
(Houston, USA).
Morphometric analyses of restenosis
According to Feldman et al,31 morphometric analyses 
were performed using the soft NDP view after scans by 
Nanozoomer from Hamamatsu (Hamamatsu City, Japan). 
Measurement of the luminal area as well as 2 areas bounded 
by the internal and external elastic lamina on HE staining 
served to compute intimal and media areas. Three indexes 
of intimal growth were used: intimal area, media area and 
the ratio between these last ones. This experiment was 
carried out on rat and rabbit stented arteries.
Statistical analysis
Each experiment was carried in triplicate at least. Data 
are presented as mean +/- standard deviation. One-way 
analysis of variance (ANOVA) with Bonferroni’s post 
hoc test was used to examine the significance of results 
between groups if their number where higher than 2 
otherwise t-test were used. A value of P <0.05 was accepted 
as statistically significant.
Results 
Dex-PBMA characterization
The synthesis leads to a homogeneous white powder 
of dextran-graft-polybutylmethacrylate copolymer 
(Dex-PBMA) soluble in a mixture of THF and water (92:8 
v/v). The coatings of Dex-PBMA on a glass coverslip, 
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CoCr disc and CoCr stent or moulding resulted in a 
transparent film, homogeneous and without cracks. 
Dex-PBMA deep-coating of stent covered each strut 
independently with very few webbing. The stent surface 
modifications were studied using SEM and contact-angle 
analysis. As shown Fig. 1A, this coating withstands to the 
crimping on the balloon and the deployment. After one 
week of incubation at 37°C and under coronary-like flow 
conditions, Dex-PBMA coating remained unaltered and 
showed a uniform polymer surface, niether pealing nor 
delamination was observed.
The coating wettability was evaluated by measuring 
water contact angles (Fig. 1B). CoCr is less hydrophobic 
(θ=88.7° ± 2.2) than Dex-PBMA with or without 
Tacrolimus (respectively θ=98.5° ± 0.4 and 99° ± 2.9, 
P = 0.0078).
Bacterial adhesion
As shown Fig. 2, Staphylococcus aureus was lower on 
Dex-PBMA than on CoCr (ratio 11, P < 0.005) and control 
collagen (ratio 4.5, P < 0.05). In contrast, more bacteria 
adhered on CoCr than on control (ratio 4.7, P < 0.005).
Adhesion of platelets and thrombin generation on 
Dex-PBMA
In static condition, platelet adhered less on Dex-PBMA 
(Fig. 3A) than on the positive control collagen (ratio 2.7, 
P < 0.0001) or on CoCr (ratio 1.39, P < 0,01). The SEM 
images showed less platelet activation on the copolymer 
than on the bare metal. Non-activated platelets are disk-
shaped. Once activated, they first take a spherical shape as 
observed on Dex-PBMA disk (Fig. 3A) before spreading 
and giving out extensions such as filopodia that can be 
observed on CoCr surface.32 In dynamic conditions, no 
platelet adhered on Dex-PBMA (Fig. 3B). Dex-PBMA 
coating does not promote platelet adhesion and activation 
in our experimental conditions.
Thrombin generation was performed on Dex-PBMA 
Fig. 1. Dex-PBMA morphology after stent coating. (A) SEM 
micrographs of dextran grafted poly(butyl methacrylate) (Dex-PBMA) 
coated stent. Stents were expanded, dip-coated, crimped on a balloon 
and expanded again. They spend 8 days in water either in static or 
under flow conditions, shear rate 1000 s-1. (B) Water contact angles 
on cobalt chrome (CoCr), Dex-PBMA or Dex-PBMA with tacrolimus 
(Dex-PBMATAC) discs. Values are mean ± SEM of 10 determinations 
** P<0.01.
Fig. 2. Bacterial adhesion on Dex-PBMA. Dex-PBMA film, CoCr 
disc and Collagen (Coll) were incubated 1h incubation at 37°C 
with a suspension of 108 UFC/mL of Staphylococcus aureus. 
After washing the remaining bacteria were cultivated on agar gel 
overnight and counted (n=3). Values are mean ± SEM of three 
determinations *P<0.05; ** P<0.01.
and CoCr. In PPP, the velocity index of thrombin 
generation was 1.9 fold lower on Dex-PBMA disc than on 
CoCr disc (Fig. 3C, P < 0.01) in presence of Tissue Factor. 
There were no differences between the two surfaces for 
thrombin generation when the assay was performed in 
PPP without Tissue Factor (Fig. 3C) or in PRP with or 
without Tissue Factor (data not shown).
Cell adhesion and proliferation onto Dex-PBMA
ECFCs and MSCs adhered less on Dex-PBMA disc than 
on CoCr disc (Fig. 4). Non-significant differences were 
obtained for intermediate adhesion (20 min incubation 
time) whereas for focal adhesion (2 hours incubation time), 
2.4 less ECFCs (Fig. 4A, P < 0.0005) and 1.6 less MSCs (Fig. 
4B, P < 0.05) adhered on Dex-PBMA compared to CoCr 
discs. The same trends were observed for cell proliferation 
(Fig. 4C and Fig. 4D). The proliferation of ECFCs and 
MSCs was greater on CoCr disc than on Dex-PBMA. In 
both cellular type and surfaces, the proportion of cells 
compared to control coating of gelatin decrease after 4 
days. Thus, CoCr or Dex-PBMA surfaces cause cells to 
grow more slowly than on control gelatin wells.
Release of tacrolimus  from Dex-PBMA
Fig. 5 shows the cumulative TAC release profile from 
ex vivo stented arteries. An extreme burst release was 
observed corresponding to 5 ng/mL (50%) after 3 hours, 
followed by a steady state reaching 10 ng/mL over 4 days.
In vivo implantation of Dex-PBMA
Rat intramuscular and intra‑aortic implantations
Dex-PBMA films were first implanted in rat abdominal 
wall to evaluate the tissue reactions after 7 and 30 days 
(Fig. 6). As shown on HE staining (Fig. 6A), a tissue 
surrounded the film at day 7 with a thickness of 40 ± 12 
µm that remain stable at day 30 (47 ± 12 µm). The low 
level of Naphthol AS-D Chloroacetate staining indicated 
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that no neutrophil granulocytes were detected in the 
tissue (Fig. 6B). The capsule is thus mainly composed by 
collagen without any evidence of inflammatory reaction 
or necrosis.
Dex-PBMA was then evaluated on a coated stent in rat 
abdominal aorta. Immediately after implantation, no acute 
thrombosis was observed. After 30 days, all Dex-PBMA or 
control CoCr stent implanted rats (n=6) survived. At day 
30, angiographies confirmed that all arteries were patent. 
As shown in Fig. 7, no thrombus was found in Dex-PBMA 
or CoCr stented arteries. Nevertheless, a small intimal 
hyperplasia was observed both on Dex-PBMA and CoCr 
stents whereas no significant differences were noticed 
in the areas of intima (0.54 ± 0.007 mm2 vs. 0.50 ± 
0.06 mm2) and media (0.40 ± 0.04 mm2 vs. 0.43 ± 0.02 
mm2) on CoCr stent and Dex-PBMA stent (Fig. 7A). No 
macrophages were emphasized in the arterial wall (CD 68 
staining, Fig. 7B). The neointima was mainly composed of 
SMCs (α-actin staining). This SMC layer was cover by an 
endothelial layer (RECA staining) on Dex-PBMA as well 
on CoCr stents (Fig. 7B). As observed in vitro, no platelets 
adhered on Dex-PBMA and we noticed the absence of 
thrombus formation.
Implantation in a rabbit model of intimal hyperplasia
Dex-PBMA or Dex-PBMATAC stents were evaluated in 
a pathological model of neointimal hyperplasia. After 
30 days the iliac arteries were patent. Hematoxylin-
eosin staining indicated a neointima (Fig. 8A). The 
measurements emphasized a higher ratio of intima and 
media areas on Dex-PBMA stent than on CoCr stent 
Fig. 3. Human platelet adhesion and thrombin generation onto 
Dex-PBMA. (A) Left panel: Platelet adhesion in static condition 
on Dex-PBMA or CoCr discs and bovine serum albumin (BSA, 
negative control). Quantification of adherent platelets after 
2h incubation at room temperature. Data are expressed as a 
percentage of adherent platelets on collagen (positive control). 
Values are mean ± SEM of three determinations. **P<0.01. 
Right panel: Environmental scanning electron micrographs of 
adherent platelets on Dex‑PBMA and CoCr. Scale bar 20 μm, 
higher magnification scale bar 2 μm. (B) Up: Dynamic adhesion 
of dioc-6 labeled platelets on Dex-PBMA and collagen coated 
glass-coverslips submitted to physiological flow (shear rate 1500 
s-1). Micrographs of adherent platelets after 0, 30, 60 and 120 s. 
Down: Quantification of the adhesion within times on Dex-PBMA 
and collagen. (C) Thrombin generation on Dex-PBMA and CoCr 
discs. Left panel: Representative curve obtained after a thrombin 
generation experiment. Parameters of thrombin generation are 
shown: Lagtime (LT in min), time to peak (tPeak in min) and 
Peak (nM). Right panel: Velocity Indexes (VI=Peak/(tPeak-LT) 
for thrombin generation in PPP in the absence or presence of 
TF (1 pM) on Dex-PBMA and CoCr. Data are expressed as a 
percentage of the results on well plate (WP). Values are mean ± 
SEM of six determinations. **P<0.01.
Fig. 4. Circulating cells adhesion and proliferation on Dex-PBMA. 
(A-B) Human endothelial colony-forming cells (ECFCs) (A) and 
mesenchymal stem cells (MSCs) (B) intermediate (20 min) and 
focal (2 h) adhesion on Dex-PBMA (black bar) and CoCr (white 
bar) discs. (C-D) ECFCs (C) and MSCs (D) proliferations after 
72h (day 3) and 96h (day 4) of culture. Data are expressed as 
a percentage of the positive control: gelatin. Values are mean ± 
SEM of 3 determinations. ***P < 0.001, **P < 0.01. 
Fig. 5. Ex vivo cumulative Tacrolimus release profile from rat 
abdominal aorta stented with Dex-PBMATAC stent for a period of 2 
hours in perfusion medium at 37°C under flow conditions (shear 
rate 1000 s-1).
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(2.39 vs 1.90). Nevertheless, with Dex-PBMATAC this ratio 
decreased (1.60 vs 2.39). On the other hand, TNF-α blood 
concentration used as a biomarker between before and 30 
days after implantation increased in CoCr stent implanted 
rabbit (+15.6 pg/mL), and remain stable for Dex-PBMA 
stent implanted rabbit (+0.53 pg/mL) and decreased for 
Dex-PBMATAC stent implanted rabbit (-4.87 pg/mL) (Fig. 
8B).
Discussion
Implantable medical devices integration is a challenge. 
Their biocompatibility relates to the specific interaction 
between the biomaterial, blood components and tissue 
vessel. In previous studies, we demonstrated that 
Dex-PBMA polymer coating improves in vitro the 
endothelial cell coverage and limits the SMC proliferation 
involved in the stent restenosis.22,23 Current complications 
on stent are not only due to stent restenosis but also to 
LST.21,33,34 Both stent geometry and position play a role in 
stent thrombosis outbreak.4,35 Stent coating itself is a major 
factor in its interactions with blood and vascular wall and 
its quality can be highly variable.35 Indeed, implanted 
commercial coated stent showed uncoated areas, craters, 
webbing or cracks.36,37 Coating integrity and mechanical 
resistance during implantation and indwell have an 
impact on long-term stent safety.14 In the present work, 
Dex-PBMA stent struts were fully and homogeneously 
coated. The coating resists to both crimping and stent 
deployment as well as under the shear stress of physiological 
flow. This behavior prevents polymer fragmentation and 
embolization in blood circulation.
Several studies underline the importance of a rapid 
re-endothelialization of the stented area.19 In humans, 
re-endothelialization is due to the proliferation and 
migration of adjacent endothelial cells (ECs), but also to 
the contribution of endothelial progenitors cells in the 
circulation blood that differentiate in ECs.38,39 For instance, 
anti-CD34-bio-engineered stents were developed to reduce 
thrombogenicity.13,40,41 Because ECFCs that differentiated 
in vitro from endothelial progenitors and MSCs allows 
wound healing, we thus investigated their adhesion and 
growth on Dex-PBMA surface. Measurement of cell 
adhesion, viability and proliferation revealed no cytotoxic 
effect.
In previous studies, a lower hydrophobic copolymer 
Fig. 6. Histopathologic evaluation for tissue biocompatibility of 
surrounding tissues after Dex-PBMA intramuscular implantation 
at 7 and 30 days. (A) Representative photos of hematoxylin-eosin 
stainings. Double arrows represent cell cap. (B) Granulocytic 
lineage labeled by naphtol AS-D Chloroacetate esterase staining 
in purple (arrow). Scale bar 100 μm.
Fig. 7. Dex-PBMA coated or bare CoCr stent implantation in rat 
abdominal aorta after 30 days. (A) Representative Hematoxylin-
Eosin stainings. L indicates the lumen, I the intima delimited by the 
lumen and internal elastic lamina (dashdotted line), M the media 
delimited by the internal and the external elastic laminas (dashed 
line) and S a strut of the stent. (B) Representatives α‑actin (smooth 
muscle cells), RECA (endothelial cells) and CD 68 (Macrophages) 
immuno-stainings. In both cases, a layer of cell proliferated in 
lumen. It was formed by SMCs and no macrophages were evident. 
An endothelium was still present. Scale bar 100 μm.
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of dextran and PBMA (θ = 79.4 ± 0.3 vs θ = 98.5° ± 0.4) 
improves in vitro the endothelial cell coverage and limits 
the SMC proliferation involved in stent restenosis.22,23 This 
difference could be explained by the control of cerium 
concentration during the synthesis. Because cerium is able 
to increase prothrombin formation, coagulation time and 
induce a proinflammatory cytokine secretion,42,43 cerium 
concentration was decreased from 0.2 M to 0.05 M and 
additional filtration steps were performed. Elementary 
analysis confirmed the decrease of the residual cerium 
concentration from 1.73 ± 0.15% to 0.069 ± 0.033%. The 
hydrophobicity of Dex-PBMA can explain the observed 
differences in vitro. Numerous works demonstrated 
the impact of the surface wettability on cell adhesion 
and proliferation.44 Nevertheless, this effect is lowered 
in vivo, by plasmatic protein deposition, mainly the 
albumin, which occurred immediately after the device 
implantation,45,46 increasing the wettability and favoring 
the material integration as observed in our in vivo study. 
Indeed, in both rat healthy aorta and rabbit pathological 
models, hyperplasia on Dex-PBMA stents were limited and 
comparable to CoCr Stents. Moreover, immunostaining 
highlighted a new endothelial cell layer in rats.
As the transcutaneous way of stent implantation may 
involve a bacterial infection risk and some lethal cases, 
bacterial adhesion was evaluated.29 However, dextran 
is known to favor bacterial adhesion and growth,47 
and functionalized polymethyl methacrylate-based 
polymers were shown to prevent it.28 S. aureus adhesion 
to Dex-PBMA CoCr disk was thus assessed and was 
equivalent to the negative control. In contrast, a higher 
rate of bacterial adhesion was observed on bare CoCr disk, 
probably due to the electropolishing surface treatment 
used for clinical stent preparation,48 which generates 
micro-scratches favoring bacterial adhesion on the 
surface. In our experimental conditions, our Dex-PBMA 
coating was shown to prevent bacterial adhesion.
Hemocompatibility is identified as a key milestone for 
a vascular device development. Platelet adhesion and 
blood coagulation are modulated by material surface.49-51 
As an example, in polylactic acid and magnesium 
scaffolds or silicone rubbers material used for the 
biomedical membrane, the thrombosis remains the 
main complication.35,52,53 The Platelet adhesion was thus 
evaluated as reflect of primary hemostasis. We studied 
either in vitro static and dynamic platelets adhesion as well 
as thrombin generation on Dex-PBMA surfaces. In static 
and dynamic conditions few platelets adhered on the 
surface coated with Dex-PBMA as compared to the bare 
metal CoCr. We then quantify thrombin generation, which 
allows us to check the influence of our copolymer on all 
the coagulation pathways. Dex-PBMA copolymer reduces 
the formation of thrombin in plasma when coated on 
CoCr, reflecting an inhibition of the coagulation pathway. 
Thus, our results showed that Dex-PBMA copolymer is 
hemocompatible and do not trigger platelets adhesion and 
activation, as well as blood coagulation.
Moreover in vivo, both in rat and rabbit models, 
histological results show the absence of acute thrombosis 
immediately after the implantation or at the time of 
Fig. 8. Dex-PBMA with or without Tacrolimus coated or bare CoCr stent implantation in rabbit iliac artery restenosis model after 30 days 
(n=1, 3 animals, preliminary study). (A) Representative Hematoxylin-Eosin stainings (Up). L indicates the lumen, I the intima delimited by 
the lumen and internal elastic lamina (dashdotted line) and M the media delimited by the internal and the external elastic laminas (dashed 
line). Quantification of intimal hyperplasia (down) on Dex-PBMA (black bar), Dex-PBMATAC (grey bar) and CoCr (white) stents. Comparison 
of areas of the intima and media and the ratio of these last ones. (B) Difference of TNFα arterial blood concentration between before stent 
implantation and 30 days letter before sacrifice.
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explantation. Therefore Dex-PBMA exhibits key factors 
for hemocompatibility.
Since several strategies are currently used to improve 
the stent efficiency by adding drug in the coating of the 
whole structure, the abluminal face or by introducing it 
into the micro-cavities,11,54 we investigated the possibility 
to use dextran-PBMA polymer as a drug delivery 
platform. Tacrolimus, a macrolide molecule loaded in 
several stents polymer stent coating,8 was chosen as a drug 
model. Under flow, we demonstrated that Dex-PBMA 
coating could act as a drug eluting platform and release 
TAC in the medium. A burst release profile (50%) within 3 
hours and a steady state over 4 days were observed. These 
results show a release profile similar to pharmacokinetic 
profiles of DESs such as the clinical Janus CarbosStent 
that releases TAC in the vascular wall tissue within the 
first hours, and then reaches the steady-state within 6 
days.8,55 The release profile depends on the initial coating 
as well as the loaded concentration in the stent.56 The 
duration of Tacrolimus release from Dex-PBMATac can be 
improve using multilayer of Dex-PBMA coating strategy 
as observed with the Cypher®21 or the Infinnium® stents.15 
In our conditions, the low loading level of the drug 
could explain the results observed in vivo in restenosis 
rabbit model where no difference was seen between 
Dex-PBMATAC and Dex-PBMA stents. Another study 
should be devoted in the future to increase the amount of 
drug and then evaluate its efficiency.
The in vivo implantation of a material and its degradation 
induce the local repair process, which involves the 
inflammation and the remodeling process.57-59 From 
the in vivo results, neither esterase staining nor TNFα 
blood cytokine modification was found. No pathologic 
inflammatory reaction was observed in the intramuscular 
position or in the aorta. Furthermore, the fibrous cap 
thickness is important in the case of drug delivery.57 A 
thicker cap decreases drug release. Dex-PBMA shows 
a moderate thickness of the fibrous cap as compared to 
other drug delivery platforms.60 Therefore Dex-PBMA 
can therefore be proposed as an interesting local drug 
delivery platform.
Conclusion
The present study shows that Dex-PBMA exhibited 
properties suitable for stent coating, resisted to mechanical 
forces required for crimping coating processes, remained 
undamaged under flow conditions and could release a 
drug. Dex-PBMA exhibited moderate platelet adhesion 
and did not trigger thrombin generation in vitro and 
allowed endothelial progenitor and MSCs proliferation. 
In vivo Dex-PBMA i) was efficient to promote endothelial 
coverage 30 days after stent implantation that might 
prevent side effects in contact with blood, ii) prevented 
pathological inflammatory reaction in a rabbit model of 
intimal hyperplasia. Dex-PBMA represents therefore a 
What is the current knowledge?
√ PBMA polymers are used in the commercial stent coating 
√ Dex-PBMA with suitable elastic properties were developed 
as a stent coating.
√ The nature of the polymer coating is involved in the major 
complications after stent implantation: restenosis and LST.
What is new here?
√ In vitro under physiological flow, Dex-PBMA is 
hemocompatible and do not trigger platelet adhesion and 
activation as well as blood coagulation 
√ Dex-PBMA stent coating remained unaltered and could 
release Tacrolimus under coronary-like flow conditions. 
√ Dex-PBMA exhibits biocompatibility properties in vivo 
in aortic stent rat model and in pathological neointimal 
hyperplasia rabbit model.
Research Highlights
new opportunity and an interesting alternative for coating 
implantable medical devices at the interface with the 
blood.
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